Severe Hypotension following Inadvertent Intravenous Administration of Interferon Alfa-2a

Package insert. Intron A (interferon alfa-2b, recombinant) for injection prescribing information. Kenilworth, NJ: Schering-Plough Corporation, January 1996.

Kirkwood J.M. , Strawderman M.H. , Ernstoff M.S. , Smith T.J. , Borden E.C. , Blum R.H. . Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7–17.

Balch C.M. , Buzaid A.C. . Finally, a successful adjuvant therapy for high-risk melanoma. J Clin Oncol 1996; 14: 1–3.

Package insert. Roferon-A (interferon alfa-2a, recombinant) prescribing information. Nutley, NJ: Roche Laboratories, September 1995.

Sparano J.A. , Fisher R.I. , Sunderland M. , Margolin K. , Ernest M.L. , Sznol M. . Randomized Phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993; 11: 1969–77.

Marincola F.M. , White D.E. , Wise A.P. , Rosenberg S.A. . Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995; 13: 1110–22.

Bates D.W. , Cullen D.J. , Laird N. , Peterson L.A. , Small S.D. , Servi D. . for the ADE Prevention Study Group. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA 1995; 274: 29–34.